Nasal sprays for treating COVID-19: a scientific note

DOI record: { "DOI": "10.1007/s43440-023-00463-7", "ISSN": [ "1734-1140", "2299-5684" ], "URL": "http://dx.doi.org/10.1007/s43440-023-00463-7", "alternative-id": [ "463" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "30 October 2022" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Revised", "name": "revised", "order": 2, "value": "6 February 2023" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 3, "value": "7 February 2023" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 4, "value": "27 February 2023" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Conflict of interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest." }, { "label": "Free to read", "name": "free", "value": "This content has been made available to all." } ], "author": [ { "ORCID": "http://orcid.org/0000-0002-7701-8597", "affiliation": [], "authenticated-orcid": false, "family": "Chavda", "given": "Vivek P.", "sequence": "first" }, { "affiliation": [], "family": "Baviskar", "given": "Kajal P.", "sequence": "additional" }, { "affiliation": [], "family": "Vaghela", "given": "Dixa A.", "sequence": "additional" }, { "affiliation": [], "family": "Raut", "given": "Shilpa S.", "sequence": "additional" }, { "affiliation": [], "family": "Bedse", "given": "Anjali P.", "sequence": "additional" } ], "container-title": "Pharmacological Reports", "container-title-short": "Pharmacol. Rep", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2023, 2, 27 ] ], "date-time": "2023-02-27T12:03:12Z", "timestamp": 1677499392000 }, "deposited": { "date-parts": [ [ 2023, 2, 27 ] ], "date-time": "2023-02-27T13:05:46Z", "timestamp": 1677503146000 }, "indexed": { "date-parts": [ [ 2023, 2, 28 ] ], "date-time": "2023-02-28T05:30:07Z", "timestamp": 1677562207700 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2023, 2, 27 ] ] }, "language": "en", "license": [ { "URL": "https://www.springernature.com/gp/researchers/text-and-data-mining", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 2, 27 ] ], "date-time": "2023-02-27T00:00:00Z", "timestamp": 1677456000000 } }, { "URL": "https://www.springernature.com/gp/researchers/text-and-data-mining", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 2, 27 ] ], "date-time": "2023-02-27T00:00:00Z", "timestamp": 1677456000000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s43440-023-00463-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s43440-023-00463-7/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s43440-023-00463-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1007", "published": { "date-parts": [ [ 2023, 2, 27 ] ] }, "published-online": { "date-parts": [ [ 2023, 2, 27 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1080/10408363.2020.1783198", "author": "M Ciotti", "doi-asserted-by": "publisher", "first-page": "365", "journal-title": "Crit Rev Clin Lab Sci", "key": "463_CR1", "unstructured": "Ciotti M, Ciccozzi M, Terrinoni A, Jiang W-C, Wang C-B, Bernardini S. The COVID-19 pandemic. Crit Rev Clin Lab Sci. 2020;57:365–88. https://doi.org/10.1080/10408363.2020.1783198.", "volume": "57", "year": "2020" }, { "DOI": "10.3906/sag-2004-127", "author": "M Hasöksüz", "doi-asserted-by": "publisher", "first-page": "549", "journal-title": "Turkish Journal of Medical Sciences", "key": "463_CR2", "unstructured": "Hasöksüz M, Kilic S, Saraç F. Coronaviruses and sars-cov-2. Turkish Journal of Medical Sciences. 2020;50:549–56.", "volume": "50", "year": "2020" }, { "DOI": "10.1016/B978-0-7020-4089-4.00072-X", "doi-asserted-by": "publisher", "key": "463_CR3", "unstructured": "Peiris JSM. Coronaviruses. Medical Microbiology 2012:587–93. https://doi.org/10.1016/B978-0-7020-4089-4.00072-X." }, { "DOI": "10.1007/978-1-4939-2438-7_1", "author": "AR Fehr", "doi-asserted-by": "publisher", "first-page": "1", "journal-title": "Methods Mol Biol", "key": "463_CR4", "unstructured": "Fehr AR, Perlman S, Maier HJ, Bickerton E, Britton P. An overview of their replication and pathogenesis; genomic organization. Methods Mol Biol. 2015;1282:1–23.", "volume": "1282", "year": "2015" }, { "DOI": "10.1016/j.cell.2020.07.012", "author": "Q Li", "doi-asserted-by": "publisher", "first-page": "1284", "journal-title": "Cell", "key": "463_CR5", "unstructured": "Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182:1284–94.", "volume": "182", "year": "2020" }, { "DOI": "10.1007/978-981-15-5936-5_1", "author": "SJ Fong", "doi-asserted-by": "publisher", "journal-title": "Artif Intell Cor Outbreak", "key": "463_CR6", "unstructured": "Fong SJ, Dey N, Chaki J. An Introduction to COVID-19. Artif Intell Cor Outbreak. 2020. https://doi.org/10.1007/978-981-15-5936-5_1.", "year": "2020" }, { "DOI": "10.1007/s13577-021-00512-4", "author": "S Kashte", "doi-asserted-by": "publisher", "first-page": "711", "journal-title": "Hum Cell", "key": "463_CR7", "unstructured": "Kashte S, Gulbake A, El-Amin Iii SF, Gupta A. COVID-19 vaccines: rapid development, implications, challenges and future prospects. Hum Cell. 2021;34:711–33. https://doi.org/10.1007/s13577-021-00512-4.", "volume": "34", "year": "2021" }, { "DOI": "10.1007/s10729-021-09563-3", "author": "T Dai", "doi-asserted-by": "publisher", "first-page": "455", "journal-title": "Health Care Manag Sci", "key": "463_CR8", "unstructured": "Dai T, Song J-S. Transforming COVID-19 vaccines into vaccination : challenges and opportunities for management scientists. Health Care Manag Sci. 2021;24:455–9. https://doi.org/10.1007/s10729-021-09563-3.", "volume": "24", "year": "2021" }, { "DOI": "10.18683/germs.2021.1280", "doi-asserted-by": "crossref", "key": "463_CR9", "unstructured": "Ayenigbara IO, Adegboro JS, Ayenigbara GO, Adeleke OR, Olofintuyi OO. The challenges to a successful COVID-19 vaccination programme in Africa. Germs 2021:427–40." }, { "DOI": "10.1097/INF.0000000000003042", "author": "M Yigit", "doi-asserted-by": "publisher", "first-page": "e134", "journal-title": "Pediatr Infect Dis J", "key": "463_CR10", "unstructured": "Yigit M, Ozkaya-Parlakay A, Senel E. Evaluation of COVID-19 vaccine refusal in parents. Pediatr Infect Dis J. 2021;40:e134–6. https://doi.org/10.1097/INF.0000000000003042.", "volume": "40", "year": "2021" }, { "DOI": "10.3389/fpubh.2021.709127", "author": "ET Tagoe", "doi-asserted-by": "publisher", "journal-title": "Front Public Health", "key": "463_CR11", "unstructured": "Tagoe ET, Sheikh N, Morton A, Nonvignon J, Sarker AR, Williams L, et al. COVID-19 vaccination in lower-middle income countries: national stakeholder views on challenges, barriers, and potential solutions. Front Public Health. 2021. https://doi.org/10.3389/fpubh.2021.709127.", "year": "2021" }, { "DOI": "10.1016/j.ijpe.2021.108193", "author": "ST Alam", "doi-asserted-by": "publisher", "journal-title": "Int J Prod Econ", "key": "463_CR12", "unstructured": "Alam ST, Ahmed S, Ali SM, Sarker S, Kabir G, Ul-Islam A. Challenges to COVID-19 vaccine supply chain: implications for sustainable development goals. Int J Prod Econ. 2021. https://doi.org/10.1016/j.ijpe.2021.108193.", "year": "2021" }, { "DOI": "10.1016/j.jhin.2021.10.019", "author": "TL Meister", "doi-asserted-by": "publisher", "first-page": "9", "journal-title": "J Hosp Infect", "key": "463_CR13", "unstructured": "Meister TL, Todt D, Brüggemann Y, Steinmann J, Banava S, Brill FHH, et al. Virucidal activity of nasal sprays against severe acute respiratory syndrome coronavirus-2. J Hosp Infect. 2022;120:9–13. https://doi.org/10.1016/j.jhin.2021.10.019.", "volume": "120", "year": "2022" }, { "DOI": "10.1038/s41586-021-03673-2", "author": "Z Ku", "doi-asserted-by": "publisher", "first-page": "718", "journal-title": "Nature", "key": "463_CR14", "unstructured": "Ku Z, Xie X, Hinton PR, Liu X, Ye X, Muruato AE, et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature. 2021;595:718–23.", "volume": "595", "year": "2021" }, { "DOI": "10.1016/S2213-2600(20)30354-4", "author": "E Pujadas", "doi-asserted-by": "publisher", "journal-title": "Lancet Respir Med", "key": "463_CR15", "unstructured": "Pujadas E, Chaudhry F, McBride R, Richter F, Zhao S, Wajnberg A, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir Med. 2020;8: e70.", "volume": "8", "year": "2020" }, { "DOI": "10.3390/pharmaceutics13101612", "author": "B Pilicheva", "doi-asserted-by": "publisher", "first-page": "1612", "journal-title": "Pharmaceutics", "key": "463_CR16", "unstructured": "Pilicheva B, Boyuklieva R. Can the nasal cavity help tackle COVID-19? Pharmaceutics. 2021;13:1612.", "volume": "13", "year": "2021" }, { "DOI": "10.4049/jimmunol.168.4.1796", "author": "AW Zuercher", "doi-asserted-by": "publisher", "first-page": "1796", "journal-title": "J Immunol", "key": "463_CR17", "unstructured": "Zuercher AW, Coffin SE, Thurnheer MC, Fundova P, Cebra JJ. Nasal-associated lymphoid tissue is a mucosal inductive site for virus-specific humoral and cellular immune responses. J Immunol. 2002;168:1796–803.", "volume": "168", "year": "2002" }, { "DOI": "10.1038/nri1439", "author": "H Kiyono", "doi-asserted-by": "publisher", "first-page": "699", "journal-title": "Nat Rev Immunol", "key": "463_CR18", "unstructured": "Kiyono H, Fukuyama S. NALT-versus Peyer’s-patch-mediated mucosal immunity. Nat Rev Immunol. 2004;4:699–710.", "volume": "4", "year": "2004" }, { "DOI": "10.1111/j.1574-695X.2007.00359.x", "author": "SC Corr", "doi-asserted-by": "publisher", "first-page": "2", "journal-title": "FEMS Immunol Med Microbiol", "key": "463_CR19", "unstructured": "Corr SC, Gahan CCGM, Hill C. M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol Med Microbiol. 2008;52:2–12.", "volume": "52", "year": "2008" }, { "DOI": "10.1007/s004289900177", "author": "Y Fujimura", "doi-asserted-by": "publisher", "first-page": "560", "journal-title": "Virchows Arch", "key": "463_CR20", "unstructured": "Fujimura Y. Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans. Virchows Arch. 2000;436:560–6.", "volume": "436", "year": "2000" }, { "DOI": "10.1517/14712598.3.3.519", "author": "JD Suman", "doi-asserted-by": "publisher", "first-page": "519", "journal-title": "Expert Opin Biol Ther", "key": "463_CR21", "unstructured": "Suman JD. Nasal drug delivery. Expert Opin Biol Ther. 2003;3:519–23.", "volume": "3", "year": "2003" }, { "DOI": "10.1146/annurev-immunol-032414-112315", "author": "A Iwasaki", "doi-asserted-by": "publisher", "first-page": "575", "journal-title": "Annu Rev Immunol", "key": "463_CR22", "unstructured": "Iwasaki A. Exploiting mucosal immunity for antiviral vaccines. Annu Rev Immunol. 2016;34:575–608.", "volume": "34", "year": "2016" }, { "DOI": "10.1038/s41587-020-0732-8", "author": "L DeFrancesco", "doi-asserted-by": "publisher", "first-page": "1242", "journal-title": "Nat Biotechnol", "key": "463_CR23", "unstructured": "DeFrancesco L. COVID-19 antibodies on trial. Nat Biotechnol. 2020;38:1242–52.", "volume": "38", "year": "2020" }, { "DOI": "10.1056/NEJMoa2035002", "author": "DM Weinreich", "doi-asserted-by": "publisher", "first-page": "238", "journal-title": "N Engl J Med", "key": "463_CR24", "unstructured": "Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384:238–51.", "volume": "384", "year": "2021" }, { "DOI": "10.1016/j.cell.2020.05.042", "author": "YJ Hou", "doi-asserted-by": "publisher", "first-page": "429", "journal-title": "Cell", "key": "463_CR25", "unstructured": "Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH III, et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell. 2020;182:429–46.", "volume": "182", "year": "2020" }, { "author": "M Birkhoff", "first-page": "729", "journal-title": "Indian J Pharm Sci", "key": "463_CR26", "unstructured": "Birkhoff M, Leitz M, Marx D. Advantages of intranasal vaccination and considerations on device selection. Indian J Pharm Sci. 2009;71:729.", "volume": "71", "year": "2009" }, { "DOI": "10.1021/acschemneuro.0c00288", "author": "R Siddiqui", "doi-asserted-by": "publisher", "first-page": "1523", "journal-title": "ACS Chem Neurosci", "key": "463_CR27", "unstructured": "Siddiqui R, Khan NA. Proposed intranasal route for drug administration in the management of central nervous system manifestations of COVID-19. ACS Chem Neurosci. 2020;11:1523–4.", "volume": "11", "year": "2020" }, { "DOI": "10.1186/2049-6958-8-46", "author": "L Bellussi", "doi-asserted-by": "publisher", "first-page": "46", "journal-title": "Multidiscip Respir Med", "key": "463_CR28", "unstructured": "Bellussi L, Cambi J, Passali D. Functional maturation of nasal mucosa: role of secretory immunoglobulin A (SIgA). Multidiscip Respir Med. 2013;8:46. https://doi.org/10.1186/2049-6958-8-46.", "volume": "8", "year": "2013" }, { "author": "M Kilian", "first-page": "99", "journal-title": "Bull Eur Physiopathol Respir", "key": "463_CR29", "unstructured": "Kilian M, Reinholdt J, Mortensen SB, Sørensen CH. Perturbation of mucosal immune defence mechanisms by bacterial IgA proteases. Bull Eur Physiopathol Respir. 1983;19:99–104.", "volume": "19", "year": "1983" }, { "DOI": "10.1177/000348948909800407", "author": "Y Kurono", "doi-asserted-by": "publisher", "first-page": "273", "journal-title": "Ann Otol Rhinol Laryngol", "key": "463_CR30", "unstructured": "Kurono Y, Fujiyoshi T, Mogi G. Secretory IgA and bacterial adherence to nasal mucosal cells. Ann Otol Rhinol Laryngol. 1989;98:273–7. https://doi.org/10.1177/000348948909800407.", "volume": "98", "year": "1989" }, { "DOI": "10.1126/scitranslmed.abf1555", "author": "Z Wang", "doi-asserted-by": "publisher", "first-page": "1555", "journal-title": "Sci Translat Med", "key": "463_CR31", "unstructured": "Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Viant C, Gaebler C, et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Translat Med. 2021;13:1555.", "volume": "13", "year": "2021" }, { "DOI": "10.1016/j.cell.2020.02.052", "author": "M Hoffmann", "doi-asserted-by": "publisher", "first-page": "271", "journal-title": "Cell", "key": "463_CR32", "unstructured": "Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.", "volume": "181", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)30251-8", "author": "R Lu", "doi-asserted-by": "publisher", "first-page": "565", "journal-title": "The Lancet", "key": "463_CR33", "unstructured": "Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020;395:565–74.", "volume": "395", "year": "2020" }, { "DOI": "10.1126/science.abb2507", "author": "D Wrapp", "doi-asserted-by": "publisher", "first-page": "1260", "journal-title": "Science", "key": "463_CR34", "unstructured": "Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–3.", "volume": "367", "year": "2020" }, { "DOI": "10.1038/s41586-020-2180-5", "author": "J Lan", "doi-asserted-by": "publisher", "first-page": "215", "journal-title": "Nature", "key": "463_CR35", "unstructured": "Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–20.", "volume": "581", "year": "2020" }, { "DOI": "10.1016/j.cell.2020.08.026", "author": "AO Hassan", "doi-asserted-by": "publisher", "first-page": "169", "journal-title": "Cell", "key": "463_CR36", "unstructured": "Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell. 2020;183:169–84.", "volume": "183", "year": "2020" }, { "DOI": "10.1164/arrd.1982.125.5.607", "author": "JK Czop", "doi-asserted-by": "publisher", "first-page": "607", "journal-title": "Am Rev Respir Dis", "key": "463_CR37", "unstructured": "Czop JK, McGowan SE, Center DM. Opsonin-independent phagocytosis by human alveolar macrophages: augmentation by human plasma fibronectin. Am Rev Respir Dis. 1982;125:607–9.", "volume": "125", "year": "1982" }, { "DOI": "10.1164/arrd.1986.133.1.136", "author": "S Jonsson", "doi-asserted-by": "publisher", "first-page": "136", "journal-title": "Am Rev Respir Dis", "key": "463_CR38", "unstructured": "Jonsson S, Musher DM, Goree A, Clinton LE. Human alveolar lining material and antibacterial defenses. Am Rev Respir Dis. 1986;133:136–40.", "volume": "133", "year": "1986" }, { "author": "JD Coonrod", "first-page": "118", "journal-title": "Semin Respir Infect", "key": "463_CR39", "unstructured": "Coonrod JD. The role of extracellular bactericidal factors in pulmonary host defense. Semin Respir Infect. 1986;1:118–29.", "volume": "1", "year": "1986" }, { "DOI": "10.1172/JCI108102", "author": "HY Reynolds", "doi-asserted-by": "publisher", "first-page": "376", "journal-title": "J Clin Investig", "key": "463_CR40", "unstructured": "Reynolds HY, Kazmierowski JA, Newball HH. Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages. J Clin Investig. 1975;56:376–85.", "volume": "56", "year": "1975" }, { "DOI": "10.1046/j.1365-2273.2000.00432.x", "author": "J Hanif", "doi-asserted-by": "publisher", "first-page": "461", "journal-title": "Clin Otolaryngol Allied Sci", "key": "463_CR41", "unstructured": "Hanif J, Jawad SSM, Eccles R. The nasal cycle in health and disease. Clin Otolaryngol Allied Sci. 2000;25:461–7.", "volume": "25", "year": "2000" }, { "DOI": "10.1016/S0169-409X(97)00058-6", "author": "N Mygind", "doi-asserted-by": "publisher", "first-page": "3", "journal-title": "Adv Drug Deliv Rev", "key": "463_CR42", "unstructured": "Mygind N, Dahl R. Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Deliv Rev. 1998;29:3–12.", "volume": "29", "year": "1998" }, { "DOI": "10.4193/RHINOL/18.021", "author": "AL Pendolino", "doi-asserted-by": "publisher", "first-page": "67", "journal-title": "Rhinol Onl", "key": "463_CR43", "unstructured": "Pendolino AL, Lund VJ, Nardello E, Ottaviano G. The nasal cycle: a comprehensive review. Rhinol Onl. 2018;1:67–76.", "volume": "1", "year": "2018" }, { "author": "NG Papadopoulos", "first-page": "215", "journal-title": "Immunol Aller Clinics", "key": "463_CR44", "unstructured": "Papadopoulos NG, Guibas GV. Rhinitis subtypes, endotypes, and definitions. Immunol Aller Clinics. 2016;36:215–33.", "volume": "36", "year": "2016" }, { "DOI": "10.1016/j.drudis.2021.07.021", "author": "VP Chavda", "doi-asserted-by": "publisher", "first-page": "2619", "journal-title": "Drug Discovery Today", "key": "463_CR45", "unstructured": "Chavda VP, Vora LK, Pandya AK, Patravale VB. Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management. Drug Discovery Today. 2021;26:2619–36. https://doi.org/10.1016/j.drudis.2021.07.021.", "volume": "26", "year": "2021" }, { "DOI": "10.1002/mco2.101", "author": "J Xi", "doi-asserted-by": "publisher", "first-page": "569", "journal-title": "MedComm", "key": "463_CR46", "unstructured": "Xi J, Lei LR, Zouzas W, April SX. Nasally inhaled therapeutics and vaccination for COVID-19: developments and challenges. MedComm. 2021;2:569–86. https://doi.org/10.1002/mco2.101.", "volume": "2", "year": "2021" }, { "DOI": "10.1152/ajplegacy.1975.229.3.721", "author": "W Silen", "doi-asserted-by": "publisher", "first-page": "721", "journal-title": "Am J Physiol", "key": "463_CR47", "unstructured": "Silen W, Machen TE, Forte JG. Acid-base balance in amphibian gastric mucosa. Am J Physiol. 1975;229:721–30. https://doi.org/10.1152/ajplegacy.1975.229.3.721.", "volume": "229", "year": "1975" }, { "DOI": "10.1152/ajplegacy.1975.229.3.754", "author": "IC Ehrhart", "doi-asserted-by": "publisher", "first-page": "754", "journal-title": "Am J Physiol", "key": "463_CR48", "unstructured": "Ehrhart IC, Parker PE, Weidner WJ, Dabney JM, Scott JB, Haddy FJ. Coronary vascular and myocardial responses to carotid body stimulation in the dog. Am J Physiol. 1975;229:754–60. https://doi.org/10.1152/ajplegacy.1975.229.3.754.", "volume": "229", "year": "1975" }, { "DOI": "10.4161/hv.27449", "author": "A Smith", "doi-asserted-by": "publisher", "first-page": "797", "journal-title": "Hum Vaccin Immunother", "key": "463_CR49", "unstructured": "Smith A, Perelman M, Hinchcliffe M. Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines. Hum Vaccin Immunother. 2014;10:797–807. https://doi.org/10.4161/hv.27449.", "volume": "10", "year": "2014" }, { "DOI": "10.1155/2016/1459394", "author": "JS de Apostólico", "doi-asserted-by": "publisher", "journal-title": "J Immunol Res", "key": "463_CR50", "unstructured": "de Apostólico JS, Lunardelli VAS, Coirada FC, Boscardin SB, Rosa DS. Adjuvants: classification, modus operandi, and licensing. J Immunol Res. 2016. https://doi.org/10.1155/2016/1459394.", "year": "2016" }, { "DOI": "10.1002/fsn3.1236", "author": "S Xiang", "doi-asserted-by": "publisher", "first-page": "3883", "journal-title": "Food Sci Nutr", "key": "463_CR51", "unstructured": "Xiang S, Fu J, Ye K, Zheng Y, Zhu X, Chen J, et al. Effect of Lactobacillus gasseri PA3 on gut microbiota in an in vitro colonic simulation. Food Sci Nutr. 2019;7:3883–91. https://doi.org/10.1002/fsn3.1236.", "volume": "7", "year": "2019" }, { "key": "463_CR52", "unstructured": "Covid-19 Vaccine Tracker: Latest Updates - The New York Times n.d. https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html (accessed October 29, 2022)." }, { "DOI": "10.1038/s41598-022-14601-3", "author": "A Castellarnau", "doi-asserted-by": "publisher", "first-page": "10210", "journal-title": "Sci Rep", "key": "463_CR53", "unstructured": "Castellarnau A, Heery GP, Seta A, Luscombe CA, Kinghorn GR, Button P, et al. Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial. Sci Rep. 2022;12:10210. https://doi.org/10.1038/s41598-022-14601-3.", "volume": "12", "year": "2022" }, { "DOI": "10.1152/ajplegacy.1975.229.6.1726", "author": "RP Durbin", "doi-asserted-by": "publisher", "first-page": "1726", "journal-title": "Am J Physiol", "key": "463_CR54", "unstructured": "Durbin RP. Letter: acid secretion by gastric mucous membrane. Am J Physiol. 1975;229:1726. https://doi.org/10.1152/ajplegacy.1975.229.6.1726.", "volume": "229", "year": "1975" }, { "DOI": "10.1088/1752-7163/abc302", "author": "FLM Ricciardolo", "doi-asserted-by": "publisher", "journal-title": "J Breath Res", "key": "463_CR55", "unstructured": "Ricciardolo FLM, Bertolini F, Carriero V, Högman M. Nitric oxide’s physiologic effects and potential as a therapeutic agent against COVID-19. J Breath Res. 2020. https://doi.org/10.1088/1752-7163/abc302.", "year": "2020" }, { "DOI": "10.3390/v13081656", "author": "JRA Paull", "doi-asserted-by": "publisher", "first-page": "1656", "journal-title": "Viruses", "key": "463_CR56", "unstructured": "Paull JRA, Luscombe CA, Castellarnau A, Heery GP, Bobardt MD, Gallay PA. Protective effects of astodrimer sodium 1% nasal spray formulation against SARS-CoV-2 nasal challenge in K18-hACE2 mice. Viruses. 2021;13:1656. https://doi.org/10.3390/v13081656.", "volume": "13", "year": "2021" }, { "DOI": "10.1089/jamp.2020.1622", "author": "JP Mitchell", "doi-asserted-by": "publisher", "first-page": "235", "journal-title": "J Aerosol Med Pulm Drug Deliv", "key": "463_CR57", "unstructured": "Mitchell JP, Berlinski A, Canisius S, Cipolla D, Dolovich MB, Gonda I, et al. Urgent appeal from international society for aerosols in medicine (ISAM) during COVID-19: clinical decision makers and governmental agencies should consider the inhaled route of administration: a statement from the ISAM regulatory and standardization issues networking group. J Aerosol Med Pulm Drug Deliv. 2020;33:235–8. https://doi.org/10.1089/jamp.2020.1622.", "volume": "33", "year": "2020" }, { "DOI": "10.1016/j.virol.2009.09.007", "author": "S Åkerström", "doi-asserted-by": "publisher", "first-page": "1", "journal-title": "Virology", "key": "463_CR58", "unstructured": "Åkerström S, Gunalan V, Keng CT, Tan Y-J, Mirazimi A. Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected. Virology. 2009;395:1–9. https://doi.org/10.1016/j.virol.2009.09.007.", "volume": "395", "year": "2009" }, { "author": "LB Mekler", "first-page": "501", "journal-title": "Acta Virol", "key": "463_CR59", "unstructured": "Mekler LB. On the problem of oncogene of tumour viruses. Acta Virol. 1975;19:501–8.", "volume": "19", "year": "1975" }, { "key": "463_CR60", "unstructured": "UK Clinical Trial Confirms SaNOtize’s Breakthrough Treatment for COVID-19 2021. https://www.businesswire.com/news/home/20210315005197/en/UK-Clinical-Trial-Confirms-SaNOtize%E2%80%99s-Breakthrough-Treatment-for-COVID-19 (accessed October 29, 2022)." }, { "DOI": "10.1016/j.niox.2013.03.007", "author": "G Regev-Shoshani", "doi-asserted-by": "publisher", "first-page": "48", "journal-title": "Nitric Oxide", "key": "463_CR61", "unstructured": "Regev-Shoshani G, Vimalanathan S, McMullin B, Road J, Av-Gay Y, Miller C. Gaseous nitric oxide reduces influenza infectivity in vitro. Nitric Oxide. 2013;31:48–53. https://doi.org/10.1016/j.niox.2013.03.007.", "volume": "31", "year": "2013" }, { "DOI": "10.1080/14787210.2021.1908127", "author": "K Shmuel", "doi-asserted-by": "publisher", "first-page": "1325", "journal-title": "Expert Rev Anti Infect Ther", "key": "463_CR62", "unstructured": "Shmuel K, Dalia M, Tair L, Yaakov N. Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: an observational prospective open label user survey. Expert Rev Anti Infect Ther. 2021;19:1325–30. https://doi.org/10.1080/14787210.2021.1908127.", "volume": "19", "year": "2021" }, { "key": "463_CR63", "unstructured": "Chulalongkorn University. A Phase I Double-blind, Randomized, Placebo-controlled Study to Evaluate Safety of Hypromellose-based Nasal Spray Solution Containing Human IgG1 Anti-SARS-CoV-2 Antibody Cocktail in Healthy Volunteers. clinicaltrials.gov; 2022." }, { "DOI": "10.1007/s10811-020-02143-y", "author": "L Pereira", "doi-asserted-by": "publisher", "first-page": "1875", "journal-title": "J Appl Phycol", "key": "463_CR64", "unstructured": "Pereira L, Critchley AT. The COVID 19 novel coronavirus pandemic 2020: seaweeds to the rescue? Why does substantial, supporting research about the antiviral properties of seaweed polysaccharides seem to go unrecognized by the pharmaceutical community in these desperate times? J Appl Phycol. 2020;32:1875–7. https://doi.org/10.1007/s10811-020-02143-y.", "volume": "32", "year": "2020" }, { "DOI": "10.1371/journal.pone.0259943", "author": "S Bansal", "doi-asserted-by": "publisher", "journal-title": "PLoS ONE", "key": "463_CR65", "unstructured": "Bansal S, Jonsson CB, Taylor SL, Figueroa JM, Dugour AV, Palacios C, et al. Iota-carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture. PLoS ONE. 2021. https://doi.org/10.1371/journal.pone.0259943.", "year": "2021" }, { "DOI": "10.1002/adma.202008304", "author": "RJA Moakes", "doi-asserted-by": "publisher", "first-page": "2008304", "journal-title": "Adv Mater", "key": "463_CR66", "unstructured": "Moakes RJA, Davies SP, Stamataki Z, Grover LM. Formulation of a composite nasal spray enabling enhanced surface coverage and prophylaxis of SARS-COV-2. Adv Mater. 2021;33:2008304. https://doi.org/10.1002/adma.202008304.", "volume": "33", "year": "2021" }, { "key": "463_CR67", "unstructured": "Eva Prieschl-Grassauer. Nasal spray works against COVID-19 variants. 21–04–2021 2021. https://www.thepharmaletter.com/article/nasal-spray-works-against-covid-19-variants? (Accessed April 25, 2021)." }, { "DOI": "10.1101/2020.12.08.416677", "author": "H Zhang", "doi-asserted-by": "publisher", "journal-title": "Bioengineering", "key": "463_CR68", "unstructured": "Zhang H, Yang Z, Xiang J, Cui Z, Liu J, Liu C. Intranasal administration of SARS-CoV-2 neutralizing human antibody prevents infection in mice. Bioengineering. 2020. https://doi.org/10.1101/2020.12.08.416677.", "year": "2020" }, { "DOI": "10.3389/fimmu.2021.815812", "author": "TG Moreira", "doi-asserted-by": "publisher", "journal-title": "Front Immunol", "key": "463_CR69", "unstructured": "Moreira TG, Matos KTF, De Paula GS, Santana TMM, Da Mata RG, Pansera FC, et al. Corrigendum: nasal administration of anti-CD3 monoclonal antibody (foralumab) reduces lung inflammation and blood inflammatory biomarkers in mild to moderate COVID-19 patients: a pilot study. Front Immunol. 2022. https://doi.org/10.3389/fimmu.2021.815812.", "year": "2022" }, { "key": "463_CR70", "unstructured": "Dr. Fabian Buller. Neurimmune and Ethris Sign Collaboration Agreement to Rapidly Develop Inhaled mRNA-based Antibody Therapy for the Treatment of Covid-19. Neurimmune AG 2020. https://www.neurimmune.com/news/neurimmune-and-ethris-sign-collaboration-agreement-to-rapidly-develop-inhaled-mrna-based-antibody-therapy-for-the-treatment-of-covid-19 (accessed April 25, 2021)." }, { "key": "463_CR71", "unstructured": "Chakraverty A. Swiss and German Team to Develop Inhaled mRNA Coronavirus Treatment. LabiotechEu 2020. https://www.labiotech.eu/trends-news/ethris-neurimmune-mrna-coronavirus/ (accessed October 29, 2022)." }, { "DOI": "10.1128/JVI.01648-20", "author": "S Matsuyama", "doi-asserted-by": "publisher", "first-page": "e01648", "journal-title": "J Virol", "key": "463_CR72", "unstructured": "Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells. J Virol. 2020;95:e01648-e1720. https://doi.org/10.1128/JVI.01648-20.", "volume": "95", "year": "2020" }, { "DOI": "10.1016/j.jiac.2020.04.007", "author": "K Iwabuchi", "doi-asserted-by": "publisher", "first-page": "625", "journal-title": "J Infect Chemother", "key": "463_CR73", "unstructured": "Iwabuchi K, Yoshie K, Kurakami Y, Takahashi K, Kato Y, Morishima T. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: report of three cases. J Infect Chemother. 2020;26:625–32. https://doi.org/10.1016/j.jiac.2020.04.007.", "volume": "26", "year": "2020" }, { "key": "463_CR74", "unstructured": "Covis Pharma. Covis Pharma B.V. Initiates Phase 3 Clinical Trial of Alvesco (Ciclesonide) Inhaler for the Treatment of COVID-19. Prnewswire 2020. https://www.prnewswire.com/news-releases/covis-pharma-bv-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19-301061105.html (accessed April 25, 2021)." }, { "key": "463_CR75", "unstructured": "Covis Pharma S.à.r.l. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection. clinicaltrials.gov; 2022." }, { "DOI": "10.1016/j.antiviral.2020.104787", "author": "L Caly", "doi-asserted-by": "publisher", "journal-title": "Antiviral Res", "key": "463_CR76", "unstructured": "Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020. https://doi.org/10.1016/j.antiviral.2020.104787.", "year": "2020" }, { "DOI": "10.21873/invivo.12134", "doi-asserted-by": "publisher", "key": "463_CR77", "unstructured": "Lehrer S, Rheinstein PH. Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2. In Vivo 2020 https://doi.org/10.21873/invivo.12134." }, { "DOI": "10.1016/j.xphs.2021.01.017", "author": "J Errecalde", "doi-asserted-by": "publisher", "first-page": "2501", "journal-title": "J Pharm Sci", "key": "463_CR78", "unstructured": "Errecalde J, Lifschitz A, Vecchioli G, Ceballos L, Errecalde F, Ballent M, et al. Safety and pharmacokinetic assessments of a novel ivermectin nasal spray formulation in a pig model. J Pharm Sci. 2021;110:2501–7. https://doi.org/10.1016/j.xphs.2021.01.017.", "volume": "110", "year": "2021" }, { "DOI": "10.1371/journal.pbio.3001060", "author": "L Kashkooli", "doi-asserted-by": "publisher", "journal-title": "PLoS Biol", "key": "463_CR79", "unstructured": "Kashkooli L, Rozema D, Espejo-Ramirez L, Lasko P, Fagotto F. Ectoderm to mesoderm transition by down-regulation of actomyosin contractility. PLoS Biol. 2021. https://doi.org/10.1371/journal.pbio.3001060.", "year": "2021" }, { "DOI": "10.4193/Rhin20.251", "author": "C Huart", "doi-asserted-by": "publisher", "first-page": "623", "journal-title": "Rhin", "key": "463_CR80", "unstructured": "Huart C, Philpott C, Konstantinidis I, Altundag A, Whitcroft KL, Trecca EMC, et al. Comparison of COVID-19 and common cold chemosensory dysfunction. Rhin. 2020;58:623–5. https://doi.org/10.4193/Rhin20.251.", "volume": "58", "year": "2020" }, { "DOI": "10.1016/j.intimp.2021.107871", "author": "H Kasiri", "doi-asserted-by": "publisher", "journal-title": "Int Immunopharmacol", "key": "463_CR81", "unstructured": "Kasiri H, Rouhani N, Salehifar E, Ghazaeian M, Fallah S. Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: a randomized, double blind clinical trial. Int Immunopharmacol. 2021. https://doi.org/10.1016/j.intimp.2021.107871.", "year": "2021" }, { "DOI": "10.1002/lary.30353", "author": "M Hosseinpoor", "doi-asserted-by": "publisher", "first-page": "2209", "journal-title": "Laryngoscope", "key": "463_CR82", "unstructured": "Hosseinpoor M, Kabiri M, Rajati Haghi M, Ghadam Soltani T, Rezaei A, Faghfouri A, et al. Intranasal corticosteroid treatment on recovery of long-term olfactory dysfunction due to COVID-19. Laryngoscope. 2022;132:2209–16. https://doi.org/10.1002/lary.30353.", "volume": "132", "year": "2022" }, { "DOI": "10.3389/fmicb.2018.02643", "author": "W Xu", "doi-asserted-by": "publisher", "first-page": "2643", "journal-title": "Front Microbiol", "key": "463_CR83", "unstructured": "Xu W, Xia S, Pu J, Wang Q, Li P, Lu L, et al. The antihistamine drugs carbinoxamine maleate and chlorpheniramine maleate exhibit potent antiviral activity against a broad spectrum of influenza viruses. Front Microbiol. 2018;9:2643. https://doi.org/10.3389/fmicb.2018.02643.", "volume": "9", "year": "2018" }, { "DOI": "10.21203/rs.3.rs-138252/v1", "doi-asserted-by": "publisher", "key": "463_CR84", "unstructured": "Torres J, Go CC, Chohan FA, L. GC, Sanchez-Gonzalez MA, Ferrer G. Chlorpheniramine maleate nasal spray in COVID-19 patients: Case Series. In Review 2021 https://doi.org/10.21203/rs.3.rs-138252/v1." }, { "DOI": "10.1176/appi.ajp.2014.12101342", "doi-asserted-by": "crossref", "key": "463_CR85", "unstructured": "Michael R. Liebowitz,Ester Salman,Humberto Nicolini NR. Effect of an Acute Intranasal Aerosol Dose of PH94B on Social and Performance Anxiety in Women With Social Anxiety Disorder. Am J Psychiatry 2014;171." }, { "key": "463_CR86", "unstructured": "VistaGen Therapeutics Inc. PH94B in the treatment of adjustment disorder with anxiety. May 27, 2020 2020. https://clinicaltrials.gov/ct2/show/NCT04404192 (accessed April 25, 2021)." }, { "DOI": "10.1176/appi.ajp.2014.12101342", "author": "MR Liebowitz", "doi-asserted-by": "publisher", "first-page": "675", "journal-title": "AJP", "key": "463_CR87", "unstructured": "Liebowitz MR, Salman E, Nicolini H, Rosenthal N, Hanover R, Monti L. Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder. AJP. 2014;171:675–82. https://doi.org/10.1176/appi.ajp.2014.12101342.", "volume": "171", "year": "2014" }, { "DOI": "10.1016/j.jinf.2021.05.009", "author": "S Winchester", "doi-asserted-by": "publisher", "first-page": "237", "journal-title": "J Infect", "key": "463_CR88", "unstructured": "Winchester S, John S, Jabbar K, John I. Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection. J Infect. 2021;83:237–79. https://doi.org/10.1016/j.jinf.2021.05.009.", "volume": "83", "year": "2021" }, { "DOI": "10.32412/pjohns.v35i2.1503", "author": "JB Lo", "doi-asserted-by": "publisher", "first-page": "11", "journal-title": "Philipp J Otolaryngol Head Neck Surg", "key": "463_CR89", "unstructured": "Lo JB, Cruz ET. Efficacy of Carragelose® nasal spray impregnated versus mupirocin ointment impregnated nasal packs on mucosal healing after endoscopic sinus surgery: a double-blind, non-randomized, right-left side comparison. Philipp J Otolaryngol Head Neck Surg. 2020;35:11.", "volume": "35", "year": "2020" }, { "DOI": "10.1038/s41467-020-20789-7", "author": "Z Ku", "doi-asserted-by": "publisher", "first-page": "469", "journal-title": "Nat Commun", "key": "463_CR90", "unstructured": "Ku Z, Xie X, Davidson E, Ye X, Su H, Menachery VD, et al. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. Nat Commun. 2021;12:469. https://doi.org/10.1038/s41467-020-20789-7.", "volume": "12", "year": "2021" }, { "DOI": "10.1038/s41590-020-0778-2", "author": "ES Winkler", "doi-asserted-by": "publisher", "first-page": "1327", "journal-title": "Nat Immunol", "key": "463_CR91", "unstructured": "Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020;21:1327–35. https://doi.org/10.1038/s41590-020-0778-2.", "volume": "21", "year": "2020" }, { "DOI": "10.1017/S0022215120002455", "author": "LA Vaira", "doi-asserted-by": "publisher", "first-page": "1123", "journal-title": "J Laryngol Otol", "key": "463_CR92", "unstructured": "Vaira LA, Hopkins C, Sandison A, Manca A, Machouchas N, Turilli D, et al. Olfactory epithelium histopathological findings in long-term coronavirus disease 2019 related anosmia. J Laryngol Otol. 2020;134:1123–7. https://doi.org/10.1017/S0022215120002455.", "volume": "134", "year": "2020" }, { "DOI": "10.2147/IJN.S313093", "author": "ZF Aref", "doi-asserted-by": "publisher", "first-page": "4063", "journal-title": "IJN", "key": "463_CR93", "unstructured": "Aref ZF, Bazeed SEES, Hassan MH, Hassan AS, Rashad A, Hassan RG, et al. Clinical, biochemical and molecular evaluations of ivermectin mucoadhesive nanosuspension nasal spray in reducing upper respiratory symptoms of mild COVID-19. IJN. 2021;16:4063–72. https://doi.org/10.2147/IJN.S313093.", "volume": "16", "year": "2021" }, { "DOI": "10.5694/mja2.51305", "author": "D Fraile Navarro", "doi-asserted-by": "publisher", "first-page": "255", "journal-title": "Med J Aust", "key": "463_CR94", "unstructured": "Fraile Navarro D, Tendal B, Tingay D, Vasilunas N, Anderson L, Best J, et al. Clinical care of children and adolescents with COVID-19: recommendations from the national COVID-19 clinical evidence taskforce. Med J Aust. 2022;216:255–63. https://doi.org/10.5694/mja2.51305.", "volume": "216", "year": "2022" }, { "DOI": "10.1139/y75-101", "author": "AH Jansen", "doi-asserted-by": "publisher", "first-page": "726", "journal-title": "Can J Physiol Pharmacol", "key": "463_CR95", "unstructured": "Jansen AH, Russell BJ, Chernick V. Respiratory effects of H+ and dinitrophenol injections into the brain stem subarachnoid space of fetal lambs. Can J Physiol Pharmacol. 1975;53:726–33. https://doi.org/10.1139/y75-101.", "volume": "53", "year": "1975" }, { "DOI": "10.1002/ppul.24748", "author": "LM Yonker", "doi-asserted-by": "publisher", "first-page": "1085", "journal-title": "Pediatr Pulmonol", "key": "463_CR96", "unstructured": "Yonker LM, Shen K, Kinane TB. Lessons unfolding from pediatric cases of COVID-19 disease caused by SARS-CoV-2 infection. Pediatr Pulmonol. 2020;55:1085–6. https://doi.org/10.1002/ppul.24748.", "volume": "55", "year": "2020" }, { "DOI": "10.1111/j.1365-2044.1994.tb04360.x", "author": "RWM Walker", "doi-asserted-by": "publisher", "journal-title": "Anaesthesia", "key": "463_CR97", "unstructured": "Walker RWM, Darowski M, Morris P, Wraith JE. Anaesthesia and mucopolysaccharidoses: a review of airway problems in children. Anaesthesia. 1994. https://doi.org/10.1111/j.1365-2044.1994.tb04360.x.", "year": "1994" }, { "DOI": "10.1542/peds.2010-0616", "author": "TR Wolfe", "doi-asserted-by": "publisher", "first-page": "532", "journal-title": "Pediatrics", "key": "463_CR98", "unstructured": "Wolfe TR, Braude DA. Intranasal medication delivery for children: a brief review and update. Pediatrics. 2010;126:532–7. https://doi.org/10.1542/peds.2010-0616.", "volume": "126", "year": "2010" }, { "DOI": "10.1016/0005-2744(75)90218-1", "author": "F Yoshimura", "doi-asserted-by": "publisher", "first-page": "167", "journal-title": "Biochim Biophys Acta", "key": "463_CR99", "unstructured": "Yoshimura F, Suzuki T. Calcium-stimulated adenosine triphosphatase in the microsomal fraction of tooth germ from porcine fetus. Biochim Biophys Acta. 1975;410:167–77. https://doi.org/10.1016/0005-2744(75)90218-1.", "volume": "410", "year": "1975" }, { "DOI": "10.1007/978-1-4614-7978-9", "doi-asserted-by": "crossref", "key": "463_CR100", "unstructured": "Kolhe P, Shah M, Rathore N, (2013). American association of pharmaceutical scientists, editors. Sterile product development: formulation, process, quality and regulatory considerations. New York: Springer : AAPS Press." }, { "DOI": "10.2105/ajph.66.1.64", "author": "JK Glenn", "doi-asserted-by": "publisher", "first-page": "64", "journal-title": "Am J Public Health", "key": "463_CR101", "unstructured": "Glenn JK, Goldman J. Task delegation to physician extenders–some comparisons. Am J Public Health. 1976;66:64–6. https://doi.org/10.2105/ajph.66.1.64.", "volume": "66", "year": "1976" }, { "DOI": "10.1002/14651858.CD013627.pub2", "author": "MJ Burton", "doi-asserted-by": "publisher", "journal-title": "Coch Database Syst Rev", "key": "463_CR102", "unstructured": "Burton MJ, Clarkson JE, Goulao B, Glenny A-M, McBain AJ, Schilder AG, et al. Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them. Coch Database Syst Rev. 2020. https://doi.org/10.1002/14651858.CD013627.pub2.", "year": "2020" }, { "DOI": "10.1007/s43441-020-00214-3", "author": "JD Momper", "doi-asserted-by": "publisher", "first-page": "282", "journal-title": "Ther Innov Regul Sci", "key": "463_CR103", "unstructured": "Momper JD, Green DJ, Park K, Burckart GJ, Snyder DL. Ethical considerations for pediatric placebo-controlled trials: FDA outcomes and perspectives. Ther Innov Regul Sci. 2021;55:282–303. https://doi.org/10.1007/s43441-020-00214-3.", "volume": "55", "year": "2021" }, { "DOI": "10.1177/0145561320932318", "author": "S Frank", "doi-asserted-by": "publisher", "first-page": "586", "journal-title": "Ear Nose Throat J", "key": "463_CR104", "unstructured": "Frank S, Capriotti J, Brown SM, Tessema B. Povidone-iodine use in sinonasal and oral cavities: a review of safety in the COVID-19 era. Ear Nose Throat J. 2020;99:586–93. https://doi.org/10.1177/0145561320932318.", "volume": "99", "year": "2020" }, { "DOI": "10.3390/vaccines9080881", "author": "RG King", "doi-asserted-by": "publisher", "first-page": "881", "journal-title": "Vaccines", "key": "463_CR105", "unstructured": "King RG, Silva-Sanchez A, Peel JN, Botta D, Dickson AM, Pinto AK, et al. Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 and fully protects mice from lethal challenge. Vaccines. 2021;9:881. https://doi.org/10.3390/vaccines9080881.", "volume": "9", "year": "2021" }, { "DOI": "10.3390/vaccines8040771", "author": "W Sun", "doi-asserted-by": "publisher", "first-page": "771", "journal-title": "Vaccines", "key": "463_CR106", "unstructured": "Sun W, McCroskery S, Liu W-C, Leist SR, Liu Y, Albrecht RA, et al. A newcastle disease virus (NDV) expressing a membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine. Vaccines. 2020;8:771. https://doi.org/10.3390/vaccines8040771.", "volume": "8", "year": "2020" }, { "DOI": "10.1093/cid/ciac448", "author": "Y Lin", "doi-asserted-by": "publisher", "journal-title": "Clin Infect Dis", "key": "463_CR107", "unstructured": "Lin Y, Yue S, Yang Y, Yang S, Pan Z, Yang X, et al. Nasal spray of neutralizing monoclonal antibody 35B5 confers potential prophylaxis against severe acute respiratory syndrome coronavirus 2 variants of concern: a small-scale clinical trial. Clin Infect Dis. 2022. https://doi.org/10.1093/cid/ciac448.", "year": "2022" }, { "DOI": "10.1080/21645515.2022.2045853", "author": "K Dhama", "doi-asserted-by": "publisher", "first-page": "2045853", "journal-title": "Hum Vaccin Immunother", "key": "463_CR108", "unstructured": "Dhama K, Dhawan M, Tiwari R, Emran TB, Mitra S, Rabaan AA, et al. COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges. Hum Vaccin Immunother. 2022;18:2045853. https://doi.org/10.1080/21645515.2022.2045853.", "volume": "18", "year": "2022" }, { "DOI": "10.3390/pharmaceutics10030082", "author": "E Touitou", "doi-asserted-by": "publisher", "first-page": "82", "journal-title": "Pharmaceutics", "key": "463_CR109", "unstructured": "Touitou E, Natsheh H, Duchi S. Buspirone nanovesicular nasal system for non-hormonal hot flushes treatment. Pharmaceutics. 2018;10:82. https://doi.org/10.3390/pharmaceutics10030082.", "volume": "10", "year": "2018" }, { "DOI": "10.3109/10611869308996066", "author": "A Harris", "doi-asserted-by": "publisher", "first-page": "101", "journal-title": "J Drug Target", "key": "463_CR110", "unstructured": "Harris A. Review: clinical opportunities provided by the nasal administration of peptides. J Drug Target. 1993;1:101–16. https://doi.org/10.3109/10611869308996066.", "volume": "1", "year": "1993" }, { "DOI": "10.1016/S0168-3659(02)00363-2", "author": "L Illum", "doi-asserted-by": "publisher", "first-page": "187", "journal-title": "J Control Release", "key": "463_CR111", "unstructured": "Illum L. Nasal drug delivery—possibilities, problems and solutions. J Control Release. 2003;87:187–98. https://doi.org/10.1016/S0168-3659(02)00363-2.", "volume": "87", "year": "2003" }, { "DOI": "10.1080/17425247.2020.1714589", "author": "B Forbes", "doi-asserted-by": "publisher", "first-page": "127", "journal-title": "Expert Opin Drug Deliv", "key": "463_CR112", "unstructured": "Forbes B, Bommer R, Goole J, Hellfritzsch M, De Kruijf W, Lambert P, et al. A consensus research agenda for optimising nasal drug delivery. Expert Opin Drug Deliv. 2020;17:127–32. https://doi.org/10.1080/17425247.2020.1714589.", "volume": "17", "year": "2020" }, { "DOI": "10.1007/s13346-020-00891-5", "author": "L-A Keller", "doi-asserted-by": "publisher", "first-page": "735", "journal-title": "Drug Deliv and Transl Res", "key": "463_CR113", "unstructured": "Keller L-A, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv and Transl Res. 2022;12:735–57. https://doi.org/10.1007/s13346-020-00891-5.", "volume": "12", "year": "2022" }, { "DOI": "10.1016/j.ijpharm.2019.118813", "author": "MY Lobaina", "doi-asserted-by": "publisher", "journal-title": "Int J Pharmaceut", "key": "463_CR114", "unstructured": "Lobaina MY. Nasal route for vaccine and drug delivery: features and current opportunities. Int J Pharmaceut. 2019. https://doi.org/10.1016/j.ijpharm.2019.118813.", "year": "2019" }, { "DOI": "10.1007/s11095-011-0417-6", "author": "V Kundoor", "doi-asserted-by": "publisher", "first-page": "1895", "journal-title": "Pharm Res", "key": "463_CR115", "unstructured": "Kundoor V, Dalby RN. Effect of formulation- and administration-related variables on deposition pattern of nasal spray pumps evaluated using a nasal cast. Pharm Res. 2011;28:1895–904. https://doi.org/10.1007/s11095-011-0417-6.", "volume": "28", "year": "2011" }, { "DOI": "10.1089/jam.2004.17.249", "author": "PG Djupesland", "doi-asserted-by": "publisher", "first-page": "249", "journal-title": "J Aerosol Med", "key": "463_CR116", "unstructured": "Djupesland PG, Skretting A, Winderen M, Holand T. Bi-directional nasal delivery of aerosols can prevent lung deposition. J Aerosol Med. 2004;17:249–59. https://doi.org/10.1089/jam.2004.17.249.", "volume": "17", "year": "2004" }, { "DOI": "10.1208/s12249-015-0317-x", "author": "K Berkenfeld", "doi-asserted-by": "publisher", "first-page": "479", "journal-title": "AAPS PharmSciTech", "key": "463_CR117", "unstructured": "Berkenfeld K, Lamprecht A, McConville JT. Devices for dry powder drug delivery to the lung. AAPS PharmSciTech. 2015;16:479–90. https://doi.org/10.1208/s12249-015-0317-x.", "volume": "16", "year": "2015" }, { "DOI": "10.1016/j.otohns.2008.03.009", "author": "SJ Kanowitz", "doi-asserted-by": "publisher", "first-page": "131", "journal-title": "Otolaryngol Head Neck Surg", "key": "463_CR118", "unstructured": "Kanowitz SJ, Batra PS, Citardi MJ. Topical budesonide via mucosal atomization device in refractory postoperative chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2008;139:131–6. https://doi.org/10.1016/j.otohns.2008.03.009.", "volume": "139", "year": "2008" }, { "key": "463_CR119", "unstructured": "Marino D. Aptar Pharma’s Nasal Unidose Device Approved by US FDA. Drug Development and Delivery 2020. https://drug-dev.com/aptar-pharmas-nasal-unidose-device-approved-by-us-fda/ (accessed October 29, 2022)." }, { "key": "463_CR120", "unstructured": "SinusTM Pulsating Aerosol System - PARI n.d. https://www.pari.com/us/products/nebulizer-systems-for-the-sinuses-and-upper-airway-us/sinus-pulsating-aerosol-system-us/ (accessed October 29, 2022)." }, { "DOI": "10.1016/j.jconrel.2012.01.024", "author": "L Illum", "doi-asserted-by": "publisher", "first-page": "254", "journal-title": "J Control Release", "key": "463_CR121", "unstructured": "Illum L. Nasal drug delivery: recent developments and future prospects. J Control Release. 2012;161:254–63. https://doi.org/10.1016/j.jconrel.2012.01.024.", "volume": "161", "year": "2012" }, { "DOI": "10.7759/cureus.10501", "doi-asserted-by": "publisher", "key": "463_CR122", "unstructured": "Westover JB, Ferrer G, Vazquez H, Bethencourt-Mirabal A, Go CC. In Vitro Virucidal Effect of Intranasally Delivered Chlorpheniramine Maleate Compound Against Severe Acute Respiratory Syndrome Coronavirus 2. Cureus 2020. https://doi.org/10.7759/cureus.10501" } ], "reference-count": 122, "references-count": 122, "relation": {}, "resource": { "primary": { "URL": "https://link.springer.com/10.1007/s43440-023-00463-7" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Pharmacology", "General Medicine" ], "subtitle": [], "title": "Nasal sprays for treating COVID-19: a scientific note", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy" }